GLP-1 Drugs May Actually Improve Bone Density in People With Diabetes | Research

The takeaway

GLP-1 receptor agonists exenatide and dulaglutide increased bone mineral density at multiple body sites over 52 weeks in type 2 diabetes patients, while placebo showed significant bone loss.

BMD increase at multiple sites
GLP-1 RAs over 52 weeks vs. significant bone loss in the placebo group

What the researchers found

GLP-1 RAs increased bone mineral density at multiple skeletal sites over 52 weeks, while placebo showed significant bone loss at the spine, femoral neck, and total hip.

Why it matters

Diabetes increases fracture risk, and some diabetes drugs worsen bone health. Finding that GLP-1 RAs may actually improve bone density adds another reason to consider these drugs for patients with type 2 diabetes.

The numbers in context

65 patients; 52 weeks; HbA1c 8.11→7.40 (exenatide), 8.77→7.06 (dulaglutide); BMD increased at L1-L4, femoral neck, total hip with GLP-1RAs

How the study worked

Single-blinded RCT with 65 T2DM patients randomized to exenatide (n=19), dulaglutide (n=19), insulin glargine (n=10), or placebo (n=17) for 52 weeks. BMD measured by dual-energy X-ray absorptiometry (DXA).

Who was studied

Type 2 diabetes patients randomized to exenatide, dulaglutide, insulin glargine, or placebo

What this study cannot tell us

Small sample size (65 total, 10-19 per group). Single-blinded design. 52-week duration may not capture long-term effects. No fracture outcomes assessed.

How to read the evidence

Small randomized clinical trial providing preliminary evidence. Supports bone-protective effects but requires larger confirmatory studies.

When this study was published

Published in 2021, contributing to understanding of GLP-1 RA effects beyond glycemic control.

The bigger picture

GLP-1 receptor agonists continue to demonstrate benefits beyond blood sugar control. Adding bone protection to their known cardiovascular and weight management benefits strengthens the case for their broader use in type 2 diabetes management.

Questions still open

Do the BMD improvements translate to reduced fracture risk in diabetic patients?
What is the mechanism by which GLP-1 RAs affect bone metabolism?
Are these bone effects maintained beyond 52 weeks?

Common questions

Do GLP-1 drugs help or hurt your bones?

This study suggests they help. GLP-1 receptor agonists like exenatide and dulaglutide increased bone density over 52 weeks, while the placebo group lost bone density. This is encouraging for diabetic patients who are already at higher fracture risk.

Should bone health influence which diabetes medication I choose?

It's one factor to consider. Some diabetes drugs (like certain thiazolidinediones) are known to weaken bones, while GLP-1 receptor agonists may actually protect bone density. Discuss with your doctor if you have osteoporosis risk factors.

Read the original research

Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.

BioMed research international, 2021, 3361309

View on PubMed ↗Publisher’s paper ↗

Citation

Cai, Ting-Ting; Li, Hui-Qin; Jiang, Lan-Lan; Wang, Hui-Ying; Luo, Meng-Hui; Su, Xiao-Fei; Ma, Jian-Hua. (2021). Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.. BioMed research international, 2021, 3361309. https://doi.org/10.1155/2021/3361309